Dynavax to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference
August 31 2020 - 4:10PM
Dynavax Technologies Corporation (Nasdaq: DVAX), a
biopharmaceutical company focused on developing and commercializing
novel vaccines, today announced that Ryan Spencer, Chief Executive
Officer, will participate in a virtual fireside chat at the H.C.
Wainwright Virtual 22nd Annual Global Investment Conference on
Monday, September 14, at 10:00 a.m. ET.
The presentation will be webcast and may be
accessed through the “Events & Presentations” page on the
“Investors” section of the Company’s website at
http://investors.dynavax.com/events-presentations.
About DynavaxDynavax is a
commercial stage biopharmaceutical company developing and
commercializing novel vaccines. The Company launched its first
commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant),
Adjuvanted], in February 2018, following U.S. FDA approval for
prevention of infection caused by all known subtypes of hepatitis B
virus in adults age 18 years and older. Dynavax is also
further developing CpG 1018 as an advanced vaccine adjuvant through
research collaborations and partnerships. Current
collaborations are focused on adjuvanted vaccines for COVID-19,
pertussis and universal influenza. For more information, visit
www.dynavax.com and follow the company on LinkedIn.
Contacts:
Nicole Arndtnarndt@dynavax.com510-665-7264
Derek Cole, President Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024